According to the World Health Organization, Alzheimer's disease accounts for 60-70% of all dementia cases in the world. Numerous studies show that cannabidiol (CBD) has great promise in the therapy of this neurodegenerative disease.
CBD interacts with endocannabinoid receptors, stimulating neural activity and promoting overall neurological health. Clinical trials have shown that CBD effectively improves behavioral symptoms associated with Alzheimer's, such as appetite problems and sleep disturbances. Further research suggests that CBD acts as an anti-inflammatory agent and antioxidant, providing additional therapeutic benefits for neuroprotection.
In a groundbreaking 2016 study, ten Alzheimer's patients were treated with CBD for four weeks, resulting in a significant reduction in neuropsychiatric symptoms from 44.9 to 12.9 on a rating scale. These reductions included reductions in aggression, agitation, hallucinations, apathy, and irritability, suggesting CBD's potential in controlling behavioral and psychological symptoms of the disease.
Moreover, research conducted on mice indicates that CBD promotes neurogenesis, the growth of new neurons, which, in turn, leads to a reduction in cognitive impairments.
It is essential to consider individual body responses when using CBD for Alzheimer's treatment. Gradually increasing the dosage under medical supervision is recommended to determine the optimal therapeutic effect without causing undesirable reactions.
As ongoing CBD research continues to unfold, this cannabinoid opens up new perspectives as a potential adjunct therapy in controlling Alzheimer's disease. However, consulting medical professionals is crucial to develop a personalized treatment plan and explore the full potential of CBD in alleviating Alzheimer's symptoms.